KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
Phase: Phase II-III clinical trials
Principal Investigator: Dott. Lo Russo Giuseppe
Main Facility: Oncologia Medica Toraco-Polmonare
Drug: Pembrolizumab
Mk2870 (sacituzumab tirumotecan)
Chemio: Carboplatin, cisplatin, pemetrexed, paclitaxel, gemcitabine (based on squamous or non-squamous histology)
ClinicalTrials.gov: Read more about clinical trials
Multicenter, open-label study that will evaluate the efficacy and safety of investigational agents with various combinations of chemotherapy and pembrolizumab in participants with newly diagnosed resectable Stages II to IIIB (N2) NSCLC (squamous and nonsquamous).
The neoadjuvant phase involves two treatment arms:
- Arm 1 (standard): Pembrolizumab + platinum based doublet
- Arm 2 (sperimental): Pembrolizumab + MK2870
All patients will undergo surgery and adjuvant treatment with pembrolizumab.
Last update: 20/04/2026